There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
Zacks.com on MSN12h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...
Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
GlobalData on MSN10h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback